A complement to kidney disease: CFHR5 nephropathy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Identification of exosome protein panels as predictive biomarkers for non-small cell lung cancer.Biological procedures online · 2023
   Article
2. C3 Glomerulopathy.Pediatric nephrology (Berlin, Germany) · 2017
   Review

Corrections and comments

• Comment on
  Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis.2010

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as